Cargando…
Risk Factors for COVID-19 Associated Mucormycosis: The Ophthalmologist’s Perspective
The COVID-19 pandemic has led to a dramatic rise in the incidence of rhino-orbito-cerebral mucormycosis (ROCM) in India. The purpose of our report is to describe the prevalence of ROCM in the context of SARS-CoV-2 infection during the second Indian COVID-19 wave, as well as its diagnostics proceedin...
Autores principales: | Bilgic, Alper, Kodjikian, Laurent, Sudhalkar, Aditya, Dwivedi, Shyamal, Vasavada, Viraj, Shah, Arpan, Dziadzko, Mikhail, Mathis, Thibaud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948853/ https://www.ncbi.nlm.nih.gov/pubmed/35330273 http://dx.doi.org/10.3390/jof8030271 |
Ejemplares similares
-
Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid
por: Bilgic, Alper, et al.
Publicado: (2021) -
Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021) -
Current intravitreal therapy and ocular hypertension: A review
por: Sudhalkar, Aditya, et al.
Publicado: (2021) -
Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab
por: Bilgic, Alper, et al.
Publicado: (2020) -
Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study
por: Bilgic, Alper, et al.
Publicado: (2021)